Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (NCT05897541), a randomized phase 3 study. The primary outcome is Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset.

2. Clinical Question

The primary endpoint combines evidence of infection with symptomatic illness. A positive central laboratory RT-PCR result alone does not meet this endpoint; the participant must also have had the specified COVID-19 symptoms. The registry definition required at least one of 14 specified symptoms for at least 48 hours, including worsening of a preexisting COVID-19-like symptom when the score increased from baseline.

The clinical contrast is between assignment to a short oral course of S-217622 and assignment to matching placebo in the stated household-contact setting. The record does not establish that every participant had the same exposure intensity or timing, and those details are not reported in the registry record. The endpoint therefore addresses the recorded outcome in the enrolled study population, rather than every possible setting or exposure circumstance.

3. Trial Design

The registry describes a completed phase 3 study with randomized allocation, double masking, and a parallel-group model. Participants were assigned to S-217622 or matching placebo. Both interventions were administered orally for 5 days. The record identifies Shionogi as the sponsor and lists an enrollment of 3701. The study start date was 2023-06-09, and primary completion was 2024-08-30.

The study question concerned prevention of symptomatic SARS-CoV-2 infection among household contacts of an individual with symptomatic COVID-19. The primary outcome was assessed from Day 1 up to Day 10. The primary analysis was defined for the mITT population, described as randomly assigned participants with a negative screening SARS-CoV-2 infection result confirmed by central laboratory RT-PCR from a sample collected before the first dose. The available population description ends mid-sentence, so further membership rules are not reported in the registry record.

The primary result reports 30.0 participants with the endpoint among 1030.0 assigned to S-217622 and 91.0 among 1011.0 assigned to placebo. These are the analysis group sizes for the primary outcome, not the overall enrollment figure. Other posted outcome measures use different analysis group sizes and, for some outcomes, different observation periods or definitions. Those differences matter when comparing results across outcomes.

Randomization and masking describe important design features, but they do not by themselves tell readers how allocation was generated or concealed, who remained masked, or how masking success was assessed. Those details are not reported in the registry record. The original sample-size rationale, planned statistical model, analysis hierarchy, interim-analysis arrangements, and handling of missing outcome data are also not reported in the registry record. The posted record lists no reported analyses for the displayed secondary comparisons.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 3701 participants were enrolled in the study, of whom 2387 were randomized to receive study drug or placebo, and 1314 were enrolled as index case participants. Per prespecified analysis, data for study primary and secondary outcome measures, all-cause mortality, and adverse events were not collected for index case participants.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Modified intention-to-treat (mITT) analysis set included all participants randomly assigned to study intervention who had a negative screening SARS-CoV-2 infection, confirmed by RT-PCR result (central laboratory) collected from a sample prior to the first dose of randomized treatment (Visit 1), were associated with index participants who did not have an exclusionary protocol deviation, and had at least 1 dose of either ensitrelvir or placebo.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Randomized HHC participants: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention. Index case participants: All index participants who had met all eligibility requirements with a signed informed consent and were associated with 1 or more participants who were randomized to receive a study intervention and who did not have any exclusionary deviations.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset, measured over Day 1 up to Day 10.

The primary endpoint counts participants in the mITT population who were infected with SARS-CoV-2 and had COVID-19 symptom onset from Day 1 up to Day 10. Infection was to be confirmed by a positive central laboratory RT-PCR result. Symptomatic COVID-19 required the occurrence, or worsening in the case of preexisting COVID-19-like symptoms, of at least one of the 14 specified symptoms for at least 48 hours.

This combined endpoint asks about symptomatic, laboratory-confirmed illness rather than infection alone. That distinction is important because infection and symptoms are related but not identical events. A participant with a positive test but no qualifying symptoms would not meet the primary definition. The registry also lists separate secondary outcomes addressing infection regardless of symptoms and other symptom-related outcomes, which provide additional context without replacing the primary endpoint.

A participant count is a direct way to report how many people met a defined event criterion in each analysis group. The comparison is expressed as a risk difference, which describes the contrast between the proportions with the event in the two groups. The primary counts were 30.0 of 1030.0 for S-217622 and 91.0 of 1011.0 for placebo. The endpoint is limited to its stated population, definition, and time window; it does not capture outcomes outside those terms.

The registry's definition uses central laboratory confirmation, a specified symptom set, and a duration threshold. Such rules make the endpoint more reproducible by setting out what qualifies as an event. They also mean that changes to testing, symptom recording, or follow-up could affect whether events are identified. Details of endpoint adjudication and missing assessments are not reported in the registry record.

7. Results Posted in the Registry

• S-217622: 2.9% (30/1030) versus 9.0% (91/1011) on control; risk difference -6.1 percentage points (95% CI -8.1 to -4.0), risk ratio 0.32 (0.22–0.48); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • S-217622: 4.4% (52/1194) versus 10.2% (122/1193) on control; risk difference -5.9 percentage points (95% CI -7.9 to -3.8), risk ratio 0.43 (0.31–0.58); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for S-217622 than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • S-217622: mean 613.70 versus 558.26 on control; difference 55.44 (95% CI 31.03 to 79.85), standardized effect d = 0.23; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for S-217622 than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • S-217622: 5.4% (56/1030) versus 13.0% (131/1011) on control; risk difference -7.5 percentage points (95% CI -10.0 to -5.0), risk ratio 0.42 (0.31–0.57); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for S-217622 than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The posted secondary outcomes extend the primary question in several directions: symptomatic infection in an ITT population, infection irrespective of symptoms, timing of the first central laboratory-confirmed positive test, positive test results, symptom status, symptom resolution, and symptom scores. These measures are related to the primary endpoint, but each addresses a different aspect of infection or illness and may use a different analysis population, follow-up period, or measurement scale.

Across the posted secondary comparisons with estimates, the direction generally aligns with the primary result: the S-217622 group has fewer participants with the listed infection outcomes, while the reported mean time to first positive result is longer. This pattern gives context to the primary finding, but it does not make the outcomes interchangeable. A count of positive tests, a combined symptomatic endpoint, and a mean time are not the same estimand. Some listed secondary outcomes do not have posted numerical analyses in the registry record, so no result should be inferred for them from the outcomes that do have comparisons.

The displayed secondary p-values are unadjusted. In general, when multiple outcomes or hypotheses are examined, the chance of at least one apparently strong result can increase unless the testing approach accounts for multiplicity. The registry does not report a prespecified hierarchy or adjustment for these secondary tests. Their results therefore carry less confirmatory weight than a primary endpoint interpreted under a clearly reported testing plan. The registry lists no reported analyses for the displayed secondary comparisons, so details of any fuller analysis are not reported in the registry record.

The secondary findings are best treated as supportive context, not as independent proof of the primary result or as a basis for claims about outcomes that were not numerically reported. Differences in analysis groups and definitions should be kept in view when considering whether the overall pattern is coherent.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset
• Number of Participants Infected With SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms
• Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result
• Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results
• Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10
• Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10
• Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms
• Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10

9. Statistical Interpretation

10. Statistical Methods Explained

The posted comparisons use different statistical summaries according to the type of outcome. The primary endpoint is a binary event: each participant either met the combined infection-and-symptom definition during the stated period or did not. The registry reports group event counts and a risk-difference comparison. Other binary outcomes use the same broad logic but have their own population, event definition, and follow-up period. The time-to-first-positive-test outcome is reported as a mean in hours, with a mean difference between groups.

What does a risk difference express?

In general, a risk difference compares the proportion of participants with an event in one group with the proportion in the other group. A value below zero for the S-217622 comparison means that the observed event proportion was lower in that group under the comparison's direction. Unlike a relative measure, a risk difference stays on the absolute probability scale. The primary registry estimate is negative, and its reported interval lies below zero. That describes the direction and statistical precision of the posted estimate; it does not itself establish clinical importance.

The primary comparison is unadjusted in the results displayed. An unadjusted comparison uses the observed group outcomes without accounting for additional covariates in a reported model. Whether the trial's original analysis included adjustments, stratification, or other modeling is not reported in the registry record. The registry's unadjusted p-value should therefore be read as the result labeled in the posted comparison, not as a complete description of every analysis that may have been specified in the original protocol.

What does a confidence interval add?

In general, a confidence interval gives a range of values compatible with the data and the statistical procedure used to calculate it. It conveys uncertainty around an estimate, whereas a p-value addresses compatibility with a particular null hypothesis under model assumptions. For the primary risk difference, the reported interval is entirely below zero, matching the direction of the point estimate. The registry does not state the confidence level in the material describing these results, so that level is not reported in the registry record.

An interval should not be interpreted as a guarantee that the true effect lies inside its endpoints, nor does it account automatically for bias, outcome misclassification, missing data, or selective reporting. Its width reflects statistical uncertainty under the calculation, not every source of uncertainty in applying the result. The analysis method and assumptions used for the interval are not reported in the registry record.

Why do the outcome definitions matter?

The primary endpoint requires both central laboratory confirmation and qualifying symptoms. The secondary outcome for participants with a central laboratory-confirmed positive result counts infection without requiring the same symptomatic endpoint. The ITT symptomatic outcome uses another analysis population and differs from the mITT primary population. Accordingly, differences among these results may arise from their definitions and analysis sets as well as from sampling variation. They should be read as related but distinct questions.

The time-to-first-positive-test result is on a time scale, not a binary risk scale. A mean difference summarizes average observed times in the specified analysis groups. It does not describe the distribution of individual times, and it may not represent the experience of participants who never had a positive result in the relevant observation period. The registry describes the outcome period as Day 1 up to Day 28 and reports the group means and standard errors. The analysis rules for participants without a positive result are not reported in the registry record.

What is the role of the p-value?

In general, a p-value measures how incompatible the observed data are with a specified null model, assuming that model and the analysis conditions are appropriate. It is not the probability that the null hypothesis is true, and it is not the probability that the result arose by chance in ordinary language. The primary comparison and the displayed secondary comparisons report unadjusted p-values of <0.001. That notation gives a threshold, not an exact p-value. The registry does not report a multiplicity-adjusted analysis for these endpoints.

Because several outcomes are listed, reading each unadjusted p-value as if it were the sole planned test can overstate the strength of the overall evidence. General statistical practice treats a prespecified outcome hierarchy or a multiplicity procedure as relevant when multiple hypotheses are tested. The trial's intended approach to multiplicity is not reported in the registry record, so no claim can be made about whether a correction was planned or applied outside the displayed results.

What do the analysis populations tell the reader?

The mITT primary population is defined using random assignment and a negative screening test confirmed before treatment. The ITT secondary outcome has a distinct label and a different number of participants in its reported analysis groups. In general, analysis populations define which participants contribute data to an outcome and can affect the estimate. The registry record does not provide a complete description of the mITT rules, a full explanation of the ITT implementation, or reasons for differences between the outcome-specific group sizes.

Overall, the statistical summaries indicate direction and uncertainty for the posted comparisons, but they do not replace the full protocol and statistical analysis plan. Those documents would be needed to assess the planned estimands, adjustments, missing-data methods, and testing sequence. These details are not reported in the registry record.

11. Confidence Intervals and Precision

The primary risk-difference estimate is negative, and its reported interval lies entirely below zero. The unadjusted p-value is <0.001. Together, the estimate and interval describe a group contrast whose direction is not close to zero under the interval calculation. The interval is not a measure of clinical importance, and the registry does not report the confidence level or the calculation method for this interval.

For the time-to-first-positive-test outcome, the posted means are 613.7 hours for S-217622 and 558.3 hours for placebo. The mean difference is 55.44 hours, with an interval from 31.03 to 79.85 hours. This interval is above zero and indicates uncertainty around the estimated difference in mean time. The reported standard errors are 7.845 and 9.672 hours for the two groups. The mean comparison and its interval apply to the analysis groups for this outcome, not automatically to everyone enrolled.

In general, a narrower interval indicates greater statistical precision for a particular estimate under its method and assumptions; a wider interval indicates more uncertainty. Precision depends on factors such as the amount and variability of data, but an interval cannot show whether the study's measurements were unbiased or whether participants with missing outcomes differed from those observed. The registry's missing-data methods and confidence-interval construction are not reported.

The statistical results are therefore precise in the limited sense conveyed by their posted estimates and intervals. Interpretation should also account for the endpoint definitions, analysis populations, unadjusted testing, and unreported analysis details. Statistical precision does not remove those limitations.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning display gives illustrative group sizes for detecting effects set at 100% of the observed effect, 75% of the observed effect, or 50% of the observed effect. For the binary outcomes, values are participants per arm. The time-to-first-positive-test planning values are also described as participants per arm; the registry's general note says time-to-event planning displays give total events, but this posted outcome is a mean, not a time-to-event measure with a reported Schoenfeld event calculation. The specific planning entries for the displayed comparisons are labeled as participants per arm.

The stated assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is the stated fraction of the observed effect. These are planning illustrations calculated from observed effects, not the original trial design assumptions. The trial's own sample-size rationale and original design assumptions are not reported in the registry record.

The 80% power column gives the illustrative participants per arm for a design that would have an 80% chance of detecting the stated effect if the assumptions and effect were correct. The 90% power column gives the corresponding planning figure for a higher target chance of detection. These are design calculations, not guarantees about a future study's result. Smaller effects require more participants to detect under the same planning assumptions, which is why the figures increase when the assumed effect is reduced from 100% to 75% or 50% of the observed effect.

This is not observed power. It does not retrospectively measure the probability that the completed trial detected its effect, and it should not be used as a substitute for reading the estimates and uncertainty intervals. The accompanying curve illustrates the planning relationship between assumed effect size and required sample size, not a new result from the trial.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.090; treatment proportion p₁ = 0.029; average p̄ = 0.060.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.3347 = 0.6560.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.3319 = 0.2794.
4. n = (0.6560 + 0.2794)² / (-0.0609)² = 236.1, rounded up to 237 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.0900098911968348                          # control proportion
p1 <- 0.029126213592233                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(5897541)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 237 (80% power), 316 (90% power)
 75% of observed effect: n per arm = 471 (80% power), 630 (90% power)
 50% of observed effect: n per arm = 1,171 (80% power), 1,568 (90% power)
power.prop.test: 236.1 
Simulated power at n = 237 per arm: 0.821 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The record lists one primary outcome and multiple secondary outcomes, with unadjusted p-values for the displayed comparisons. It does not report a testing hierarchy, a family-wise error procedure, or another multiplicity adjustment. When several statistical tests are conducted, the chance of obtaining at least one small p-value can rise; a planned hierarchy or adjustment can address that issue. Without the prespecified approach, the secondary p-values should not be read as though each were the only hypothesis tested.

The registry fields for the displayed secondary comparisons contain no reported analyses. This does not establish that no analyses were performed; it means the analysis details are not reported in the registry record. The original statistical analysis plan, including model specifications and any adjusted or sensitivity analyses, is not reported in the registry record.

Missing-data procedures are also not reported in the registry record. It is therefore not possible to determine from the posted information how incomplete symptom records, absent tests, withdrawals, or other missing outcome information were handled. General statistical methods for missing data can make different assumptions about outcomes that are unobserved, and those assumptions can affect estimates. No particular method or assumption should be attributed to this trial without documentation.

The primary population is identified as mITT and has a stated screening-test criterion, but the registry's description of that population is truncated. The ITT secondary outcome has different analysis group sizes from the primary outcome. Further details of population membership, exclusions, and reasons for outcome-specific denominators are not reported in the registry record. The registry also does not report interim-analysis arrangements or stopping rules.

These gaps do not erase the posted group counts and estimates, but they limit assessment of how the results relate to the full prespecified analysis strategy. A protocol and statistical analysis plan would be needed to evaluate those decisions in detail.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: colitis (0.1%), hepatic enzyme increased (0.1%), umbilical hernia (0.1%), pneumonia (0.1%), urinary tract infection (0.1%).

The registry reports serious adverse events for 1190 participants at risk in the S-217622 group and 1187 in the placebo group. Serious adverse events were reported for 3 participants in the S-217622 group and 2 in the placebo group. Deaths were 0 in each group. Other adverse events are reported as 0 for both groups, among the listed participants at risk.

The serious-event terms listed include Colitis, Hepatic enzyme increased, Umbilical Hernia, Pneumonia, and Urinary Tract Infection, each shown as 0.1%. The registry does not assign those terms to a specific treatment group in the information listed, so they should not be attributed to either group. The record does not provide a full event-by-event narrative or details about severity, timing, relatedness, or handling of recurrent events.

These figures are descriptive safety counts. They do not by themselves establish that an event was caused by the assigned intervention, nor do they rule out risks that are uncommon or not captured in the posted record. The registry's definitions and analysis methods for adverse events are not reported in the registry record.

16. What the Result Does, and Does Not, Mean

The posted primary outcome shows fewer observed participants meeting the combined laboratory-confirmed infection and symptom definition in the S-217622 group than in the placebo group. The negative risk-difference estimate and its interval below zero describe the direction of that comparison, and the unadjusted p-value is <0.001. The interpretation applies to the study's mITT population, endpoint definition, and period from Day 1 up to Day 10.

The result does not establish that every participant assigned to S-217622 avoided infection or symptoms. It does not address every possible exposure circumstance or population. The trial concerned household contacts of an individual with symptomatic COVID-19, and the posted endpoint required both a positive central laboratory RT-PCR result and qualifying symptoms. Infection without symptoms is addressed by a different secondary outcome.

A statistically clear difference is not automatically a statement about clinical importance. The registry result does not, by itself, show how the observed contrast should be valued in a particular clinical or public-health setting. It also does not establish the durability of any difference beyond the reported outcome periods. The registry lists other outcomes through Day 28, but those outcomes have distinct definitions and analysis sets.

The posted findings do not eliminate uncertainty about missing outcomes, analysis choices, multiplicity, or the trial's original statistical plan, because those details are not reported in the registry record. Nor do the results alone establish effectiveness in populations or circumstances not represented by this study. The findings are statistical evidence about the recorded comparison, not medical advice or a recommendation to use or avoid a treatment.

17. Why This Trial Matters Statistically

This trial illustrates why an endpoint definition matters as much as the label attached to an outcome. The primary measure requires both laboratory-confirmed infection and sustained qualifying symptoms. Separate secondary measures address infection without requiring symptoms, timing of a positive test, and symptom-related outcomes. Those distinctions help readers see that “infection” and “symptomatic infection” answer different questions.

The trial also shows why analysis populations and denominators need to be read outcome by outcome. The primary mITT comparison and the ITT secondary comparison use different group sizes, while the time-to-first-positive-test outcome has its own analysis groups. Results should not be compared as if every outcome used the same participants and event definition.

Finally, the record demonstrates the value of statistical reporting beyond a p-value. Counts, group sizes, effect estimates, and uncertainty intervals allow readers to consider direction and precision. But incomplete reporting of multiplicity, missing-data methods, the original analysis plan, and details of population membership restricts a full assessment. The strength of statistical interpretation depends both on the numerical results and on transparent descriptions of how they were planned and analyzed.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report the original sample-size justification, the planned statistical models, an interim-analysis plan, or a multiplicity strategy. The planning illustrations are based on observed effects and stated assumptions, so they should not be mistaken for the trial's original design rationale. The statistical analysis plan is not reported in the registry record.

The mITT population description is incomplete in the registry record, ending before all potential criteria are stated. The record also gives no detailed explanation for the differences among the outcome-specific analysis group sizes. Missing-data methods, reasons for missing assessments, and sensitivity analyses are not reported. These omissions limit evaluation of the possible effects of participant exclusions and incomplete follow-up.

The posted secondary comparisons are unadjusted, and the registry lists no reported analyses for them. Several listed secondary outcomes have no numerical results in the available record, so the overall evidence across the full outcome set cannot be assessed from the posted comparisons alone. The registry also does not provide detailed methods for the confidence intervals or the time-to-first-positive-test analysis.

Finally, the results are tied to household contacts, the stated symptom and laboratory definitions, and the specified observation periods. The posted information does not establish how the findings apply beyond those conditions. These are limits on interpretation of the registry record, not proof that the underlying study did not address these matters elsewhere.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection — NCT05897541.
• Registry record last updated 2026-10-07; status last verified 2026-09.
• Results first posted 2026-09-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

NCT05897541 is a completed randomized, double-blind, parallel-group phase 3 study sponsored by Shionogi. It compared oral S-217622 for 5 days with matching placebo for 5 days among household contacts of an individual with symptomatic COVID-19. The registry lists enrollment of 3701.

The primary endpoint counted mITT participants with central laboratory-confirmed SARS-CoV-2 infection and qualifying COVID-19 symptoms from Day 1 up to Day 10. The posted counts were 30.0 among 1030.0 in the S-217622 group and 91.0 among 1011.0 in the placebo group. The reported risk-difference interval lies below zero, and the unadjusted p-value is <0.001.

Posted secondary comparisons generally point in the same direction, but they use different outcomes and analysis groups, and their p-values are unadjusted. Details of multiplicity, missing-data handling, the original statistical plan, and the complete primary population definition are not reported in the registry record. The findings should be interpreted within the stated population, endpoint definitions, and follow-up periods.